Annexon: Perfect Complement To A Speculative Biotech Portfolio

Annexon is considered a high-risk/high-reward investment, primarily due to two promising near-term therapies, with tanruprubart for Guillain-Barré syndrome (GBS) being particularly noteworthy. Tanruprubart has demonstrated highly significant Phase 3 results, showing a 2.4-fold improvement in GBS-DS compared to placebo and a strong safety profile, positioning it as a potential standard-of-care treatment. Regulatory filings are in progress, with a Marketing Authorization Application (MAA) submitted to the European Medicines Agency (EMA) and a Biologics License Application (BLA) planned for submission to the FDA in 2026. These filings are supported by ongoing FORWARD and real-world evidence studies. Annexon's cash runway extends into the second half of 2027, sufficient to support key upcoming catalysts. The company plans for in-house U.S. commercialization and is considering ex-U.S. partnerships.